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Abstract
Background Gadobutrol is a gadolinium-based contrast
agent, uniquely formulated at 1.0 mmol/ml. Although there
is extensive safety evidence on the use of gadobutrol in adults,
few studies have addressed the safety and tolerability of gad-
obutrol in pediatric patients.
Objective This subanalysis of data from the GARDIAN study
evaluated the safety and use of gadobutrol in pediatric patients
(age <18 years).
Materials and methods The GARDIAN study was a large
phase IV non-interventional prospective multicenter post-
authorization safety study performed in Europe, Asia,
North America and Africa. A total of 23,708 patients
were included who were scheduled to undergo cranial
or spinal MRI, liver or kidney MRI, or MR angiography
with gadobutrol enhancement. The primary study end-
point was the overall incidence of adverse drug reactions
(ADRs) and serious adverse events (SAEs) following
gadobutrol administration.
Results The GARDIAN study included 1,142 children
(age <18 years) who received gadobutrol at a mean
dose of 0.13 (range 0.04–0.50) mmol/kg body weight.
Gadobutrol was well tolerated in these children, with
low rates of ADRs (0.5%) and no SAEs, consistent with
results in adults enrolled in the GARDIAN study. Rates
of adverse events and ADRs were unrelated to pediatric
age or gadobutrol weight-adjusted dose. There were no
symptoms suggestive of nephrogenic systemic fibrosis.
Investigators rated the contrast quality of gadobutrol-
enhanced images as good or excellent in 97.8% of pe-
diatric patients, similar to the main study population.
Conclusion Gadobutrol is very well tolerated and provides
excellent contrast quality at the recommended weight-
adjusted dose in children (age <18 years), similar to the profile
in adults.
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Introduction
Gadobutrol (Gd-DO3A-butrol, Gadovist®, Gadavist®; Bayer
Pharma, Leverkusen, Germany) is a second-generation gado-
linium-based contrast agent (GBCA) used to enhance tissue
contrast in MRI for a range of approved indications in adults
and children of all ages [1]. Gadobutrol recently (January
2015) received approval from the U.S. Food and Drug
Administration (FDA) for use in MRI of the central nervous
system in children younger than 2 years, and gadobutrol is
approved in many other countries, including those in the
European Union (EU), for whole-body MRI in this age group
[2].
Gadobutrol is an extracellular non-ionic macrocyclic para-
magnetic contrast agent that is uniquely formulated at
1.0 mmol/ml, i.e. twice the gadolinium concentration of other
currently licensed GBCAs. Combined with its high relaxivity,
gadobutrol provides the highest T1-shortening effect per mil-
liliter compared with conventional GBCAs, which contributes
to an increase in signal intensity [3, 4]. The more compact
bolus shape permitted by the higher (1 M) gadolinium con-
centration is associated with enhanced image quality in faster
imaging techniques [5, 6]. The macrocyclic structure of gad-
obutrol provides greater stability of the chelate and reduced
release of gadolinium ions compared with linear GBCAs [7].
Release of gadolinium ions has been associated with the de-
velopment of nephrogenic systemic fibrosis (NSF) in people
with impaired renal function [8, 9]. In view of these charac-
teristics, gadobutrol has been placed by the American College
of Radiology, European Medicines Agency (EMA), and the
European Society of Urogenital Radiology in the lowest risk
category for development of NSF [10–12].
The recommended standard dose of gadobutrol for intrave-
nous injection is 0.1 mmol/kg body weight, with doses up to
0.3 mmol/kg body weight approved for specific indications in
adults. At these doses, the efficacy and safety of gadobutrol
have been demonstrated in numerous clinical studies in adults
[1, 13, 14]. By contrast, there have been few studies of gado-
butrol in pediatric patients [1, 15]. In the absence of direct
evidence, strategies for use of contrast agents in the pediatric
population [16] are typically extrapolated from adult studies.
GARDIAN (Gadovist® in Routine Diagnostic MRI –
Administration in Non-selected Patients; NCT01095081)
was a prospective large-scale multicenter non-interventional
study initiated at the request of the German authority, when
the label in the EU was extended to use in pediatric patients.
The study was designed to evaluate the safety and tolerability
of gadobutrol use in approved indications in people requiring
routine contrast-enhanced MRI [17]. The main study results
from GARDIAN, excluding the pediatric data, are reported
elsewhere [17]. The current subanalysis focuses on children
(<18 years), with the primary aim to investigate the incidence
of adverse events (AEs), adverse drug reactions (ADRs) and
serious adverse events (SAEs) in this population. The contrast
quality of gadobutrol was also assessed by the study
investigators.
Materials and methods
GARDIAN was a phase IV non-interventional prospec-
tive multicenter post-authorization safety study [17]. In
this post-approval commitment, data were planned to be
collected on at least 20,000 patients in total, including
at least 600 children younger than 18 years and 100
children younger than 8 years. Bayer Pharma provided
funding for the study design, data collection, data man-
agement and data evaluation of the GARDIAN study
and the current study subanalysis.
Ethical approval
Local ethics committee/institutional review board approval
was obtained at each study site. Prior to study enrollment each
child or guardian provided written informed consent for the
child’s data to be used for scientific purposes, consistent with
the ethical principles of the Declaration of Helsinki and the
International Conference of Harmonisation guidelines, Good
Clinical Practice (ICH-GCP). The study additionally adhered
to guidelines of the EMA, the FDA and local laws and
regulations.
Participants
Between August 2010 and April 2013, boys and girls
younger than 18 years who were scheduled to undergo
approved use of gadobutrol in cranial or spinal MRI,
liver or kidney MRI, or MR angiography were recruited
from 272 study centers in 17 countries across Europe,
Asia, North America and Africa (Table 1). Gadobutrol
was administered according to usual clinical practice,
with no additional diagnostic or monitoring processes
for study purposes. Children with contraindications as
stated in the Summary of Product Characteristics for
Gadovist (e.g., hypersensitivity to the active substance
or to any of the excipients) were excluded. Children with
moderate or severe renal impairment (estimated glomer-
ular filtration rate [GFR]: 30–59 or <30 ml/min/1.73 m2,
respectively) were scheduled for follow-up investigation
after 3 months in accordance with routine practice, at the
discretion of the treating physician.
Outcome measures
Patient data (demographics, medical data, safety param-
eters, treatment signs and symptoms) were documented
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by the treating physician, nurse or other eligible person
during the MR visit. Details on the contrast medium
intravenous injection (dose, amount and flow rate) and
physician assessment of contrast quality were also
recorded.
ADRs and SAEs were the primary study outcomes.
The rates, quality and symptoms of AEs and ADRs were
recorded over approximately 1 day from the administra-
tion of gadobutrol and were coded using the standardized
Medical Dictionary for Regulatory Activities (MedDRA,
version 13.0). AEs were defined as any undesirable out-
comes that occurred during or after administration of
gadobutrol, while ADRs were AEs that were considered
by the treating physician to be attributable to gadobutrol
administration. The categorization and severity of AEs
and ADRs were based on the judgment of the treating
physician. Secondary safety outcomes included ADR
rates analyzed by the gadobutrol dose administered and
by medical indication.
To monitor patients at high risk for NSF in this observa-
tional trial, a set of questions was provided to investigators to
assess the children’s precise renal conditions. Any skin reac-
tions suggestive of NSF were compulsorily followed up by
investigators as AEs.
The image quality was rated subjectively by investigators
on a four-point scale (poor, moderate, good or excellent).
Statistical analyses
Descriptive analyses were performed on non-missing contin-
uous (median, mean, standard deviation, maxima and minima,
upper and lower quartiles) and categorical data (frequency
tables).
Event rates for AEs and ADRs in children were calculated
as a proportion of the pediatric study population. All enrolled
subjects who were administered at least 1 dose of gadobutrol
were included in the safety population. Only patients who
underwent an MRI/MR angiography scan were included in
the efficacy population. Statistical analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Baseline demographics
A total of 23,708 patients in the main GARDIAN study were
administered at least 1 unit of gadobutrol [17]. Of these, 4.8%
(n=1,142) were pediatric patients younger than 18 years.
Pediatric patients were mainly enrolled from Europe
(56.9%), followed by Asia (37.2%) and other regions (5.9%)
(Table 1). Most children were in the age range of 7 years to
younger than 18 years (84.9%), while 14.7%were ages 2 years
to younger than 7 years, and 0.4% were younger than 2 years
(Table 2).
Risk factors for contrast medium reaction in children
included allergy (n= 81), bronchial asthma (n= 25) and
history of contrast medium reaction (n= 1). Concomitant
cardiac conditions in the pediatric population included
systemic arterial hypertension (n = 6), heart failure
(n = 3), cardiac arrhythmia (n = 2) and coronary heart
disease (n = 2). No children with severe renal impair-
ment were included; six children with moderate renal
impairment (GFR 30–59 ml/min/1.73 m2) were included.
Acute renal failure was reported in one child (age 12.4 years)
and no child was on dialysis.
Gadobutrol dose details
The mean gadobutrol dose delivered was 0.13 mmol/kg body
weight, with a range of ≤0.1 mmol/kg in 510 children
(44.7%), >0.1–0.2 mmol/kg in 551 (48.3%), >0.2–
0.3 mmol/kg in 67 (5.9%) and >0.3 mmol/kg body weight
(i.e. above the approved dose) in 14 (1.2%) (Table 3). Mean
gadobutrol doses categorized by pediatric age group were
0.21 (range 0.11–0.33) mmol/kg for <2 years, 0.13 (0.06–
0.50) mmol/kg for 2 years to <7 years and 0.13 (0.04–0.36)
mmol/kg for 7 years to <18 years.
Table 1 Number of pediatric patients per country (safety population)
Country Total number of pediatric
patients (n, % by region)
Asia 425 (37.2)
China 156 (36.7)





Bosnia & Herzegovina 28 (4.3)








Other regions 67 (5.9)
Canada 63 (94.0)
South Africa 4 (6.0)
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Adverse events (primary endpoint)
AEs were reported in 8 of the 1,142 (0.7%) children in the
safety population. Individual AEs included vomiting (n=3,
0.26%), nausea (n=2, 0.18%), and injection-site reaction, ur-
ticaria, dyspnea and eyelid edema (n=1 each, 0.09%); one
child had two AEs (nausea and vomiting). The severity and
relationship of the AEs are described in Table 4. Five children
experienced AEs of mild maximum intensity, while the re-
maining AEs were of moderate maximum intensity. No AEs
were rated severe or serious. Complete recovery was achieved
in all eight children who reported an AE, with no action re-
quired for the majority of these events (66.7%). One AE (eye-
lid edema) persisted for 5 h and was treated pharmacological-
ly, and another two AEs (vomiting and nausea) received other
treatments and did not extend beyond 5 min in duration.
Among the children with risk factors for contrast medium
reaction, one child in the 2- to <7-year range with bronchial
asthma experienced vomiting, which was assessed as unrelat-
ed to the study drug. Another child, in the 7- to <18-year age
Table 2 Demographics and
baseline characteristics of the
pediatric safety population
Demographic data N (%) pediatric patients/
median values
Total patients 1,142
Gender (n, %) Male 604 (52.9)
Female 538 (47.1)
Age groups (n [%], years) <18 years (total) 1,142 (100)
<2 years 4 (0.4)
2 – <7 years 168 (14.7)
7 – <18 years 970 (84.9)
Body weight (median, kg) <18 years (total) 45.0
<2 years 9.5
2 – <7 years 18.5
7 – <18 years 50.0
BMI (median, kg/m2) <18 years (total) 19.0
<2 years 19.1
2 – <7 years 15.7
7 – <18 years 19.7
At least 1 contrast medium risk factor
(n [% of age subgroup])
<18 years (total) 95 (8.3)
<2 years 0
2 – <7 years 12 (7.1)
7 – <18 years 83 (8.6)




Previous contrast medium reaction 1 (0.1)
BMI body mass index
Table 3 Dose groups in the
pediatric safety population Dose group (mmol/kg
body weight)
<2 years, n (%) 2 – <7 years, n (%) 7 – <18 years, n (%) Total, N (%)
≤0.1 0 88 (52.4) 422 (43.5) 510 (44.7)
>0.1 – 0.2 3 (75.0) 64 (38.1) 484 (49.9) 551 (48.3)
>0.2 – 0.3 0 10 (6.0) 57 (5.9) 67 (5.9)
>0.3a 1 (25.0) 6 (3.6) 7 (0.7) 14 (1.2)
Total 4 (100) 168 (100) 970 (100) 1,142 (100)
a Above the approved dose
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group, with concomitant allergy, experienced eyelid edema,
which was assessed as related to the study drug.
Of the eight children with AEs, six were classified with an
ADR (0.5% of the 1,142 pediatric population) (Table 4). No
association was observed between the gadobutrol dose and the
frequency of AEs or ADRs (Table 3).
No skin reactions suggestive of NSF were reported in any
child in this study.
MRI examinations and contrast medium injection
Themean injection rate in children was 1.45ml/s (range 0.00–
5.00 ml/s), with an automatic injector used in 20.9%. The
magnetic field strength used was 1.5 T in most cases
(63.4%), followed by 3 T (17.0%), 1 T (12.9%) or other
strengths (6.8%). Most investigations in the pediatric popula-
tion were for suspected tumors (52.9%), followed by inflam-
matory disease (13.8%), tumor staging (5.6%), trauma (5.2%),
infarction (1.9%) and multiple sclerosis (1.8%), with other
indications in the remainder (18.8%). The brain and spine
were investigated in 77.7% of patients, the vessels using MR
angiography in 19.4%, kidneys in 1.6%, liver in 1.2% and
others in 0.1%.
The contrast quality of gadobutrol-enhanced images was
evaluated subjectively by physicians as excellent in 63.7%,
good in 34.0%, moderate in 2.2% and poor in 0.1% of the
children.
Discussion
GARDIAN is a non-interventional MRI study that has pro-
vided the largest analysis of safety and tolerability for the
routine use of gadobutrol in clinical practice. As observed in
adults enrolled in GARDIAN [17], gadobutrol was very well
tolerated in children, with low rates of AEs (0.7%) and ADRs
(0.5%), and no SAEs. Rates of AEs and ADRs were unrelated
to gadobutrol weight-adjusted dose and age in the pediatric
population. The contrast quality of gadobutrol-enhanced im-
ages was good or excellent in almost all children (97.8%),
similar to the main study population [17].
The incidence of ADRs in children was slightly lower than
in the main GARDIAN study (0.5% vs. 0.7%). This is con-
sistent with a lower rate of contrast medium reactions in chil-
dren compared with adults in the large retrospective analyses
by Dillman et al. [18] and Davenport et al. [19]. A prospective
open-label study of gadobutrol conducted by Hahn et al. [15]
in 138 children ages 2–17 years reported an ADR incidence of
5.8% during a 1-week follow-up, with the lowest rates report-
ed in the younger age group (2–6 years, 2.2%). The higher
ADR incidence in the Hahn et al. [15] study compared with
the current observational study may be attributed to its design
as a controlled phase I/III study that included a longer follow-
up duration, pre-defined in the study protocol. In an observa-
tional study like the GARDIAN study, mostly acute reactions
are captured because no additional interventions, e.g., labora-
tory value analyses, are possible to uncover other potential
AEs. It can be assumed that the ADR rate of gadobutrol in
the GARDIAN study reflects the rate of allergy-like reactions.
This contributes toward the lower rate of AEs in children in
general and as compared to randomized clinical trials [15, 20].
Consistent with the current study, low AE rates have been
reported for other GBCAs including gadodiamide,
gadopentetate dimeglumine, gadobenate, dimeglumine,
gadoteridol and gadoversetamide in children [19, 21–25].
All ADRs reported in children in the GARDIAN study
were of mild to moderate intensity, consistent with Hahn
et al.’s [15] findings. Vomiting and nausea were the most
common ADRs, as is reported in the adult literature on
GBCAs [17, 26]. The GARDIAN study reported no NSF-
related signs or symptoms in either children or adults.
Limitations of the GARDIAN study include the potential
for under-reporting of AEs or ADRs, especially those of mild
severity, which is a feature of observational studies. Lack of
long-term follow-up in all children, low numbers of children
younger than 2 years and the use of a subjective evaluation of
Table 4 Adverse event (AE) and
adverse drug reaction (ADR)









Female/17 Nausea and vomiting 0.11 Yes Mild
Male/6 Vomiting 0.13 Yes Moderate
Male/13 Nausea 0.11 Yes Mild
Female/15 Eyelid edema 0.10 Yes Moderate
Female/5 Urticaria 0.11 Yes Moderate
Female/14 Injection-site reaction 0.11 Yes Mild
Female/5 Vomiting after 15 min 0.10 No Mild
Male/13 Dyspnea after 24 h 0.10 No Mild
Pediatr Radiol (2016) 46:1317–1323 1321
image quality by a heterogeneous group of reviewers are ad-
ditional limitations. The advantages of GARDIAN are its
large sample size that included 1,142 children (age <18 years).
In addition, the inclusion of a large number of centers from
various geographic regions helps overcome the limitations of
bias encountered in AE reports from single-center, single-
indication studies and increases the representativeness of the
results. Finally, the non-interventional design of this study
reflects the use of gadobutrol in contemporary practice.
Conclusion
The results of this large pediatric subanalysis confirm
that gadobutrol is a very well-tolerated GBCA that pro-
vides excellent contrast quality at the recommended
weight-adjusted dose (0.1 mmol/kg body weight) in chil-
dren (age <18 years), similar to the outcomes in adults
enrolled in GARDIAN. Low rates of AEs and ADRs and
no SAEs related to gadobutrol were reported in these
children. Gadobutrol is concluded to be an appropriate
contrast agent for imaging of children in routine clinical
practice, requiring no further dose adjustment according
to age.
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